drug · antibody
DUPIXENT
updated 5mo ago/ dew-PIL-oo-mab /
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 30 investigational indications.
targets
Interleukin-4 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying DUPIXENT
- phase3A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
- —Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
- phase3A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
- phase4A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- phase2Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
- —A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
- phase3Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
- —A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
News(10)
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 2d ago
- Sanofi, Regeneron broaden alliance to find their next DupixentThe deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.biopharma_dive · 2d ago
- Pfizer’s eczema drug clears skin in mid-stage trialDetailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.biopharma_dive · 2d ago
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…biospace · 2d ago
- Sanofi builds on immunology alliance with Regeneron for $1B upfrontAs the patent cliff for Dupixent draws closer, Sanofi is turning back to the partnership that built the megablockbuster. The French pharma will pay $1 billion upfront to expand its antibody collabo…endpoints · 3d ago
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.stat · 3d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 3d ago
- Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trialWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 3d ago
- Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goalConnect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks—although the study missed a secondary endpoint tied…fiercebiotech · 4d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that